Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lirentelimab - Allakos

Next Previous
X
Search
Drug Profile

Lirentelimab - Allakos

Alternative Names: AK 002; Antolimab

Latest Information Update: 31 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Allakos
  • Class Anti-infectives; Anti-inflammatories; Antiallergics; Antiasthmatics; Antibodies; Antifibrotics; Eye disorder therapies; Food allergy immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Mast cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic gastroenteritis; Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Chronic obstructive pulmonary disease; Chronic urticaria; Conjunctivitis; Eosinophilic gastroenteritis; Eosinophilic oesophagitis; Fibrosis; Keratoconjunctivitis; Systemic mastocytosis

Most Recent Events

  • 31 Jan 2024 Discontinued - Phase-I for Conjunctivitis in USA (IV)
  • 31 Jan 2024 Discontinued - Phase-I for Eosinophilic gastroenteritis (In volunteers) in Australia (IV)
  • 31 Jan 2024 Discontinued - Phase-I for Eosinophilic gastroenteritis (In volunteers) in USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top